Venovenous ECMO is a lifesaving technique for patients with severe respiratory failure. Management of carbon dioxide (CO) levels at ECMO start is crucial, as recent studies found an association between rapid CO shifts and increased incidence of neurological complications.: To describe the role of end tidal CO (etCO) monitoring at the ECMO start to minimize carbon dioxide shifts.: Retrospective cohort study. We performed a retrospective analysis of patients who started venovenous ECMO support at our institution between 2011 and 2021. We analysed the minute-by-minute variations of etCO, ventilatory parameters and arterial blood gas before and after the ECMO start. 36 patients with a complete dataset of parameters were included. After the ECMO start, minute ventilation was progressively reduced from 10.8±;3.3 to 2.9±1.2 L/min (p<0.001). etCO did not vary significantly (baseline 37±10 vs 35±9 mmHg 20 minutes after ECMO start, p = 0.36). Despite a stable etCO level, a mild drop of arterial CO tension (9.5 mmHg, corresponding to a 18% change) was recorded at the first ABG sampled after the ECMO start. No patient developed neurological complications after the ECMO commencement. etCO monitoring during ECMO start is feasible and allows to adjust gas flow and ventilator settings to limit changes in arterial CO levels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/02676591221079508 | DOI Listing |
Sci Rep
January 2025
Department Emergency and Critical Care Medicine, Changhua Christian Hospital, Changhua, 50006, Taiwan.
Extracorporeal cardiopulmonary resuscitation (ECPR) improves survival for prolonged cardiac arrest (CA) but carries significant risks and costs due to ECMO. Previous predictive models have been complex, incorporating both clinical data and parameters obtained after CPR or ECMO initiation. This study aims to compare a simpler clinical-only model with a model that includes both clinical and pre-ECMO laboratory parameters, to refine patient selection and improve ECPR outcomes.
View Article and Find Full Text PDFWe review the case of a 58-year-old female on extracorporeal membrane oxygenation (ECMO) support diagnosed with invasive pulmonary aspergillosis (IPA). Intravenous isavuconazole was started, requiring dose escalation to achieve isavuconazole trough concentration (ISA-Cmin) within the therapeutic range (2.5-5.
View Article and Find Full Text PDFComput Biol Med
January 2025
Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Medical Faculty, RWTH Aachen University, Forckenbeckstraße 55, 52074, Aachen, Germany.
The combination of extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT) pose complex hemodynamic challenges in intensive care. In this study, a comprehensive lumped parameter model (LPM) is developed to simulate the cardiovascular system, incorporating ECMO and CRRT circuit dynamics. A parameter identification framework based on global sensitivity analysis (GSA) and multi-start gradient-based optimization was developed and tested on 30 clinical data points from eight veno-arterial ECMO patients.
View Article and Find Full Text PDFGen Thorac Cardiovasc Surg Cases
January 2025
Department of Cardiovascular Surgery, Osaka General Medical Center, Osaka, 558-8558, Japan.
Background: Left atrial dissection is a rare and occasionally fatal complication of cardiac surgery and is defined as the creation of a false chamber through a tear in the mitral valve annulus extending into the left atrial wall. Some patients are asymptomatic, while others present with various symptoms, such as chest pain, dyspnea, and even cardiac arrest. Although there is no established management for left atrial dissection, surgery should be considered in patients with hemodynamic disruption.
View Article and Find Full Text PDFEur Heart J Case Rep
January 2025
Department of Cardiology, York Hospital, WellSpan Health, 30 Monument Rd, York, PA 17403, USA.
Background: ROS1 tyrosine kinase inhibitors are one of the primary immunotherapies for fusion-positive cancers. Tyrosine kinase inhibitors have markedly improved outcomes for advanced cancers previously with poor prognosis. Entrectinib is an example of an ROS1 inhibitor that can be used for lung adenocarcinoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!